caa a22 4500 469116757 CHVBK 20180323133126.0 cr unu---uuuuu 170328e19920601xx s 000 0 eng 10.1007/BF00172769 doi (NATIONALLICENCE)springer-10.1007/BF00172769 Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults [Elektronische Daten] [David Stewart, Herman Hugenholtz, Vasco DaSilva, Brian Benoit, Michael Richard, Shailendra Verma, Robert Earhart, Lucille Robillard] Twenty patients with astrocytomas recurrent after surgery ± radiation were treated on a phase II protocol of the new anthracycline derivative menogaril 115 mg/m2 administered intravenously once per week. Sixteen patients were evaluable for treatment efficacy. No patient achieved a major therapeutic response. Three patients (19%) had stable disease for greater than 8 weeks, including one who showed minor evidence of tumor regression, but less than 50%. Thirteen patients failed. Treatment was well tolerated. One patient developed granulocytopenia, while none developed thrombocytopenia. Four patients required an interruption in their treatment for one to two weeks because of development of granulocytopenia (one patient) or other reasons. Other toxic effects included arm vein phlebitis and skin irritation, skin discoloration of the infused arm, mild to moderate nausea and vomiting, diarrhea, stomatitis, and a fatal central venous catheter infection. Despite the fact that menogaril appeared to have therapeutic activity against recurrent astrocytomas in our phase I studies, we could not document any activity in this phase II study. Kluwer Academic Publishers, 1992 phase II menogaril astrocytoma nationallicence Stewart David The Ontario Cancer Treatment and Research Foundation Ottawa Regional Cancer Centre, Canada aut Hugenholtz Herman University of Ottawa Faculty of Medicine, Canada aut DaSilva Vasco University of Ottawa Faculty of Medicine, Canada aut Benoit Brian University of Ottawa Faculty of Medicine, Canada aut Richard Michael University of Ottawa Faculty of Medicine, Canada aut Verma Shailendra The Ontario Cancer Treatment and Research Foundation Ottawa Regional Cancer Centre, Canada aut Earhart Robert The Upjohn Pharmaceutical Company Ltd, Canada aut Robillard Lucille University of Ottawa Faculty of Medicine, Canada aut Journal of Neuro-Oncology Kluwer Academic Publishers 13/2(1992-06-01), 183-188 0167-594X 13:2<183 1992 13 11060 https://doi.org/10.1007/BF00172769 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00172769 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Stewart David The Ontario Cancer Treatment and Research Foundation Ottawa Regional Cancer Centre, Canada aut NATIONALLICENCE 700 1- Hugenholtz Herman University of Ottawa Faculty of Medicine, Canada aut NATIONALLICENCE 700 1- DaSilva Vasco University of Ottawa Faculty of Medicine, Canada aut NATIONALLICENCE 700 1- Benoit Brian University of Ottawa Faculty of Medicine, Canada aut NATIONALLICENCE 700 1- Richard Michael University of Ottawa Faculty of Medicine, Canada aut NATIONALLICENCE 700 1- Verma Shailendra The Ontario Cancer Treatment and Research Foundation Ottawa Regional Cancer Centre, Canada aut NATIONALLICENCE 700 1- Earhart Robert The Upjohn Pharmaceutical Company Ltd, Canada aut NATIONALLICENCE 700 1- Robillard Lucille University of Ottawa Faculty of Medicine, Canada aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 13/2(1992-06-01), 183-188 0167-594X 13:2<183 1992 13 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer